INSIGHTS ON CONTRACT PHARMA MANUFACTURING

CONTRACT PHARMA MANUFACTURING SOLUTIONS

  • The pressure to file an IND makes accelerated Phase I safety testing a priority. With the Quick to Clinic program, Thermo Fisher Scientific can deliver your large molecule drug substance for First-in-Human studies in as little as 12 months. Now you can meet important milestones – such as filing the IND – or secure additional funding with all the confidence your project needs and, we can supply. Because helping you reduce the time it takes to get your discovery to the patients who need it matters, our Quick to Clinic for Biologics is made with speed and flexibility.

  • Successful drug product development should integrate formulation, manufacturing process, primary packaging, device and delivery to the patient. Lonza’s Drug Product Services (DPS) offering delivers a holistic approach to DP development that anticipates and prevents problems early, and ensures the result is a product that is fit for purpose.

  • At Lonza, we understand the challenges facing biotherapeutic and vaccine manufacturers related to the time and costs inherent in the drug discovery and development process. Light Path™ Custom Material Supply Services are efficient, focused technology and production offerings for the Preclinical and Phase I stages of novel biologics development.

  • Lonza’s global R&D center for mammalian cell processes is based in Slough, UK alongside a custom manufacturing facility. Lonza undertakes highly specialized development and manufacturing services for the pharmaceutical and biotechnology industries. Read more about Lonza’s complete range of R&D Services and an array of technologies and skills to best match their customers’ requirements for all stages of product development.

  • When it comes to HPAPI, you will notice that we operate with a quiet confidence that comes from years of experience with HPAPI and cytotoxic drug products. At Pii we have learned that every successful HPAPI project begins with a deep understanding of the data.